Join
Live feed
·
INSIDERFilingvia Quantisnow
Xilio Therapeutics Inc. logo

Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $6,841 worth of shares (6,954 units at $0.98) (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
XLO· Xilio Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XLO (Xilio Therapeutics Inc.) and more on Quantisnow.